Posts  / #POST-207067
REDDIT

MIRA - Pharmaceuticals shares trading higher after efficacy results from Ketamir in its diabetes-associated nerve damage

Mira Pharmaceuticals (MIRA) said Wednesday that data demonstrated the potential efficacy of its oral ketamine analog, Ketamir-2, in treating diabetic neuropathy in animal model.

The study showed the drug treatment significantly reduced neuropathic pain symptoms with type 2 diabetes, the company said.

The company said it plans to start a phase 2a trial in diabetic neuropathy patients by the end of the year, with first human efficacy data expected in H1 next year. Concurrently, it aims to develop a topical slow-release formulation designed to provide localized pain relief.

Mira shares were up 25% in recent premarket activity on Wednesday.